GAD1 is a biomarker for benign and malignant prostatic tissue

Jaraj, Sara Jonmarker; Augsten, Martin; Häggarth, Lars; Wester, Kenneth; Pontén, Fredrik; Östman, Arne; Egevad, Lars

doi:10.3109/00365599.2010.521189

Cited by 18 publications

(14 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased GAD65 expression is a poor prognostic factor for both 1-year survival rates and mean survival times after surgery in patients with cholecystic cancer (10). Similar findings have also been reported in colon (11), breast (12), and prostate cancers (13). To the best of our knowledge, there are no reports of GAD 65 expression in SCLC, and the further accumulation of such cases is needed.…”

Section: Discussionsupporting

confidence: 64%

Small Cell Lung Cancer Expressing Glutamate Decarboxylase with Latent Autoimmune Diabetes in Adults

et al. 2015

View full text Add to dashboard Cite

Small cell lung cancer (SCLC) causes paraneoplastic syndromes, such as diabetes mellitus, by eliciting the expression of various antibodies including anti-glutamate decarboxylase (GAD) antibody. A 62-year-old woman presented to our hospital with a 1-week history of progressive dyspnea and difficulty in walking. Computed tomography showed a tumor obstructing the left bronchus and obstructive lung abscesses with pleural effusions. A biopsy during bronchoscopy revealed SCLC, and the clinical stage was ultimately determined to be IIIB. SCLC was complicated by diabetes mellitus with high titers of serum anti-GAD antibody. An immunohistochemical analysis showed GAD expression in the cancer cells, which is a novel finding.

show abstract

Section: Discussionsupporting

confidence: 64%

Small Cell Lung Cancer Expressing Glutamate Decarboxylase with Latent Autoimmune Diabetes in Adults

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Furthermore, high CMIP levels were associated with worse prognosis (recurrence-free and overall survival) in gastric and breast cancers [43,45] and were related with herceptin resistance in HER2-positive gastric cancer cells [46]. Similarly, the enzyme encoded by GAD1 gene, which catalyzes the conversion of L-glutamic acid to γ-aminobutyric acid, has been found overexpressed in several types of tumors, including lung adenocarcinoma [47], nasopharyngeal carcinoma [48], oral squamous cell carcinoma [49], prostate cancer [50], and brain metastasis [51], being also found upregulated in colon and HCC cells in vitro [52]. In parallel, high GAD1 levels were also shown to correlate with the pathological stage of patients with lung adenocarcinoma, positively correlating with metastasis and with worse recurrence-free survival [47].…”

Section: Discussionmentioning

confidence: 99%

Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis

Lapitz

Arbelaiz

O’Rourke³

et al. 2020

Cells

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) comprises a group of heterogeneous biliary cancers with dismal prognosis. the etiologies of most CCAs are unknown, but primary sclerosing cholangitis (PSC) is a risk Cells 2020, 9, 721 2 of 33 factor. Non-invasive diagnosis of CCA is challenging and accurate biomarkers are lacking. We aimed to characterize the transcriptomic profile of serum and urine extracellular vesicles (EVs) from patients with CCA, PSC, ulcerative colitis (UC), and healthy individuals. Serum and urine EVs were isolated by serial ultracentrifugations and characterized by nanoparticle tracking analysis, transmission electron microscopy, and immunoblotting. EVs transcriptome was determined by Illumina gene expression array [messenger RNAs (mRNA) and non-coding RNAs (ncRNAs)]. Differential RNA profiles were found in serum and urine EVs from patients with CCA compared to control groups (disease and healthy), showing high diagnostic capacity. the comparison of the mRNA profiles of serum or urine EVs from patients with CCA with the transcriptome of tumor tissues from two cohorts of patients, CCA cells in vitro, and CCA cells-derived EVs, identified 105 and 39 commonly-altered transcripts, respectively. Gene ontology analysis indicated that most commonly-altered mRNAs participate in carcinogenic steps. Overall, patients with CCA present specific RNA profiles in EVs mirroring the tumor, and constituting novel promising liquid biopsy biomarkers.

show abstract

“…Jaraj et al investigated the expression of GAD67 (GAD1) in the prostate and found that GAD67 expression was significantly higher in malignant and benign prostatic tissue than in non-prostatic control tissues. It was suggested that GAD67 may serve as a highly prostate-specific tissue biomarker (22). However, whether GAD 65 (GAD2) plays a similar role in malignancies of the gallbladder remains unknown.…”

Section: Discussionmentioning

confidence: 99%

Ornithine decarboxylase and glutamate decarboxylase 65 as prognostic markers of gallbladder malignancy: A clinicopathological study in benign and malignant lesions of the gallbladder

Deng

Pei

2012

Molecular Medicine Reports

View full text Add to dashboard Cite

Abstract. Ornithine decarboxylase (ODC) plays a critical role in cell proliferation and is overexpressed in a variety of cancers. Furthermore, γ-aminobutyric acid (GABA) content and glutamate decarboxylase (GAD) activity are increased in neoplastic tissues in colon and breast cancer. However, few studies have examined these molecules in gallbladder cancer specimens. We observed the expression levels of ODC and GAD65 in benign and malignant lesions of the gallbladder and investigated their clinicopathological significance for the first time. The expression levels of ODC and GAD65 in specimens from gallbladder adenocarcinoma (n=108), peritumoral tissues (n=46), adenomatous polyps (n=15) and chronic cholecystitis (n=35) were detected using immunohistochemical methods. Kaplan-Meier survival and Cox regression analyses were carried out to explore the clinical and pathological correlations. The levels of positive staining of ODC and GAD65 were significantly higher in gallbladder adenocarcinoma than in peritumoral tissues, adenomatous polyps and chronic cholecystitis. The Kaplan-Meier survival analysis and Cox regression analysis showed that the expression of ODC and GAD65 correlated significantly with the one-year survival rate and the mean survival time of the patients postoperatively. We conclude that the overexpression of ODC and GAD65 are significant in the carcinogenesis and progression of gallbladder adenocarcinoma. They may be important biological markers for the evaluation of biological behaviors and the prognosis of gallbladder adenocarcinoma.

show abstract

GAD1 is a biomarker for benign and malignant prostatic tissue

Abstract: GAD1 is expressed in benign and malignant prostatic tissue and may serve as a highly prostate-specific tissue biomarker.

Cited by 18 publications

References 35 publications

Small Cell Lung Cancer Expressing Glutamate Decarboxylase with Latent Autoimmune Diabetes in Adults

Small Cell Lung Cancer Expressing Glutamate Decarboxylase with Latent Autoimmune Diabetes in Adults

Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis

Ornithine decarboxylase and glutamate decarboxylase 65 as prognostic markers of gallbladder malignancy: A clinicopathological study in benign and malignant lesions of the gallbladder

Contact Info

Product

Resources

About